ANIP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANIP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ANI Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $53.4 Mil. Its Revenue for the three months ended in Dec. 2023 was $131.7 Mil.
ANI Pharmaceuticals's COGS to Revenue for the three months ended in Dec. 2023 was 0.41.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ANI Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 was 59.42%.
The historical data trend for ANI Pharmaceuticals's COGS-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
COGS-to-Revenue | Get a 7-Day Free Trial | 0.31 | 0.42 | 0.47 | 0.44 | 0.37 |
ANI Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
COGS-to-Revenue | Get a 7-Day Free Trial | 0.39 | 0.35 | 0.36 | 0.36 | 0.41 |
ANI Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 181.513 | / | 486.816 | |
= | 0.37 |
ANI Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 53.42 | / | 131.654 | |
= | 0.41 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (NAS:ANIP) COGS-to-Revenue Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
ANI Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 is calculated as:
Gross Margin % | = | 1 | - | COGS to Revenue |
= | 1 | - | Cost of Goods Sold / Revenue | |
= | 1 | - | 53.42 / 131.654 | |
= | 59.42 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Thank you for viewing the detailed overview of ANI Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Muthusamy Shanmugam | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Meredith Cook | officer: SR. VP, GENERAL COUNSEL & SEC. | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Krista Davis | officer: SVP, CHIEF HR OFFICER | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Christopher Mutz | officer: HEAD OF RARE DISEASE | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Chad Gassert | officer: SVP - CORP. DEV. & STRATEGY | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Ori Gutwerg | officer: SVP, GENERICS | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
James G. Marken | officer: Vice President, Operations | 210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623 |
Matthew J Leonard | director | 7 CUSTOM HOUSE STREET, PORTLAND ME 04101 |
Meridian Venture Partners Ii Lp | 10 percent owner | |
Nikhil Lalwani | director, officer: PRESIDENT & CEO | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623 |
Antonio R Pera | director | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623 |
Stephen P. Carey | officer: Vice President and CFO | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Renee P Tannenbaum | director | 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054 |
Jeanne Thoma | director | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Patrick D Walsh | director | 14282 FRANKLIN AVE., TUSTIN CA 92780 |
From GuruFocus
By Business Wire Business Wire • 05-12-2023
By Business Wire Business Wire • 08-03-2022
By GuruFocus Research • 11-08-2023
By Business Wire Business Wire • 05-11-2023
By Business Wire Business Wire • 08-30-2022
By Marketwired • 10-30-2023
By Business Wire Business Wire • 05-22-2023
By GuruFocus Research • 11-17-2023
By Business Wire Business Wire • 04-26-2023
By Business Wire Business Wire • 11-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.